All Posts

Every antibody discovery CRO deck I've seen in the past 18 months has at least one slide with "AI-enabled" or "ML-powered" stamped across it. Some of these claims are legit. Others are... creative marketing. If you're a biotech startup evaluating vendors, you need to separate signal from noise fast. AI can absolutely accelerate parts of your antibody campaign, but only if you know what it can (and can't) realistically do, and if you structure the engagement correctly. Here's

Outsourcing antibody discovery to a CRO can accelerate your timeline and conserve internal resources: but only if the oversight is done right. Most expensive mistakes in CRO partnerships aren't science failures. They're project management failures. Missed milestones. Unclear deliverables. Data that doesn't support your next decision. These aren't inevitable costs of outsourcing: they're avoidable with the right oversight structure from day one. Here are five proven project ma

You've decided to outsource antibody discovery. Smart move, most startups don't have the bandwidth (or budget) to build out full discovery infrastructure in-house. But now comes the tricky part: actually working with a CRO without losing control of your program. This isn't just about finding someone who can run assays. It's about setting up a partnership that moves your program forward on time, on budget, and without the rework that kills momentum. Here's how to get it right

Biotech startups face a critical decision early in development: build internal antibody discovery capabilities or outsource to contract research organizations (CROs). The choice impacts timelines, capital allocation, and ultimately, success probability. Most founders underestimate what DIY antibody discovery actually requires. The DIY Approach: Hidden Costs and Complications Building in-house antibody discovery capabilities sounds attractive. Control over intellectual prope

Choosing the right Contract Research Organization (CRO) for antibody discovery can make or break your program. Pick the wrong partner, and you're looking at missed timelines, wasted capital, and candidates that fail downstream. Pick the right one, and you accelerate your path to the clinic with high-quality leads and reliable data. But with dozens of CROs claiming expertise in antibody development, how do you actually evaluate them? Here are the seven criteria that matter mos